PANITUMUMAB
Coronary Heart Disease
Brigham and Women's Hospitalmonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Coronary Heart Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ezetimibe Canadian Collaborative Research Network | Phase 4 | BBB |
Rosuvastatin Canadian Collaborative Research Network | Phase 4 | BB |
Acarbose University of Oxford | Phase 4 | BB |
Mazdutide China National Center for Cardiovascular Diseases | Phase 4 | BB |
ADVICOR COMPONENT NIACIN University of Oxford | Phase 3 | BB |
LAROPIPRANT University of Oxford | Phase 3 | B |
Liraglutide King's College London | Phase 2 | B |
Acetylsalicylic Acid Bayer | D |
Same molecule, other indications
PANITUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →